Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 7/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10196582 | 0.88 | THRA (0.40) | DHODHFAAHMAPTPLA2G2ALMNA | |
| SCHEMBL10196117 | 0.87 | MEN1 (0.43) | HSD17B10MAPTPLA2G2ALMNA | |
| SCHEMBL10161338 | 0.85 | HPGD (0.46) | PTPN1HPGDALOX15HSD17B10MAPT | |
| SCHEMBL13072201 | 0.80 | CNR2 (0.41) | FAAHHPGDCYP1A2CYP2C19 | |
| SCHEMBL10196586 | 0.78 | ATM (0.42) | FAAHMAPTPLA2G2ALMNACYP1A2 | |
| SCHEMBL13417394 | 0.74 | FAAH (0.42) | FAAHMAPTLMNACYP1A2CYP2C9 | |
| SCHEMBL10196157 | 0.74 | THRA (0.40) | HPGDMAPTPLA2G2ACYP1A2CYP2C9 | |
| SCHEMBL10107515 | 0.74 | LMNA (0.44) | FAAHMAPTLMNACYP1A2CYP2C9 | |
| SCHEMBL10161340 | 0.73 | THRA (0.42) | PTPN1HPGDHSD17B10MAPTLMNA | |
| SCHEMBL13072442 | 0.73 | THRA (0.45) | DHODHHSD17B10PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115819-A1 | Pentacycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-10 | — | — | US | disclosed |
| WO-2010132670-A2 | PENTACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115819-A1 | Pentacycline Compounds | TSLP, IL5, IL17A | PTPN1 1410/4885DHODH 1600/4885FAAH 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.